Henry's parents founded a non-profit organization to combat Alternating Hemiplegia of Childhood (AHC), a rare and severe neurological disorder caused by a mutation in the ATP1A3 gene. The organization focuses on raising funds to develop gene therapy treatments, specifically antisense oligonucleotides (ASOs), which can modify gene expression in the nervous system. This treatment aims to correct the ion imbalance in the brain responsible for AHC, potentially changing the lives of affected individuals. The non-profit operates in the healthcare sector, targeting families and individuals affected by rare genetic disorders. Its business model relies on donations and fundraising events to finance research and development of these life-changing treatments. The organization generates revenue through charitable contributions, grants, and partnerships with research institutions.

Keywords: AHC, gene therapy, neurological disorder, ATP1A3 mutation, antisense oligonucleotides, fundraising, non-profit, rare disease, healthcare, treatment development.